Global Malaria Diagnostics - Strategic Business Report (2023 to 2030): China's Malaria Diagnostics Market on the Rise, Poised for Significant Growth
26 juil. 2023 05h33 HE
|
Research and Markets
Dublin, July 26, 2023 (GLOBE NEWSWIRE) -- The "Malaria Diagnostics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global Malaria Diagnostics...
Malaria Diagnostics Global Market to 2030: Increasing Demand for Diagnostic Tools in Malaria-endemic Countries Drives Growth
22 juin 2023 05h58 HE
|
Research and Markets
Dublin, June 22, 2023 (GLOBE NEWSWIRE) -- The "Malaria Diagnostics Market Size, Share & Trends Analysis Report 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.The global...
Taglich Brothers Initiates Coverage of Ocean Biomedical, Inc.
31 mai 2023 09h30 HE
|
Taglich Brothers Inc
NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Taglich Brothers, Inc. announces that it has initiated coverage of Ocean Biomedical, Inc. (NASDAQ: OCEA). Ocean Biomedical, Inc. headquartered in...
FFF Enterprises Inc. and RightNow Inventory™ Become Vital Members of the Artesunate for Injection Distribution Network
08 mars 2023 13h34 HE
|
FFF Enterprises.com
Temecula, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- FFF Enterprises Inc., the nation’s most trusted specialty drug distributor, today announced that it has partnered with Amivas (US), LLC to stock...
Ocean Biomedical to Ring The Nasdaq Stock Market Opening Bell
16 févr. 2023 08h01 HE
|
Ocean Biomedical, Inc.
Ocean Biomedical commenced trading on Nasdaq under ticker symbol "OCEA" on February 15 Providence, RI and New York, NY, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical (“the Company”),...
Malaria Pipeline Clinical Trials Featuring 35+ companies| DelveInsight
04 janv. 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Malaria Pipeline Clinical Trials Featuring 35+ companies| DelveInsight Malaria is one of the most widespread life-threatening diseases, commonly...
BioNTech beginnt klinische Phase-1-Studie mit Malaria-Impfstoffprogramm BNT165
23 déc. 2022 03h00 HE
|
BioNTech SE
BioNTechs Ziel ist es, den ersten mRNA-basierten Impfstoff zur Prävention von Malaria zu entwickeln, der auf einem neuartigen Multi-Antigen-Impfstoffansatz basiert.Der erste in der Klinik untersuchte...
BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165
23 déc. 2022 03h00 HE
|
BioNTech SE
BioNTech aims to develop the first mRNA-based vaccine for Malaria prevention based on a novel multi-antigen vaccine approachFirst evaluated candidate BNT165b1 expresses certain parts of the...
BioNTech beginnt Bau der ersten Produktionsstätte für mRNA-basierte Impfstoffe in Afrika
23 juin 2022 06h00 HE
|
BioNTech SE
Spatenstich in Kigali, Ruanda, für BioNTechs erste modulare mRNA-Produktionsstätte in Afrika; Lieferung der ersten Containermodule für Ende 2022 geplantAuf Einladung von Paul Kagame, Präsident der...
BioNTech Starts Construction of First mRNA Vaccine Manufacturing Facility in Africa
23 juin 2022 06h00 HE
|
BioNTech SE
Breaking of Ground for BioNTech’s initial African modular mRNA manufacturing facility in Kigali, Rwanda; delivery of first container modules planned for end of 2022On invitation by H.E. President Paul...